$729 Million is the total value of Consonance Capital Management LP's 26 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $98,001,000 | +159.5% | 761,762 | +78.5% | 13.45% | +139.4% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $63,277,000 | -5.0% | 1,599,109 | +3.4% | 8.68% | -12.3% |
| TARO | Sell | TARO PHARMACEUTICAL INDS LTD | $47,886,000 | -9.8% | 311,234 | -17.7% | 6.57% | -16.7% |
| CSII | Buy | CARDIOVASCULAR SYS INC DEL | $45,914,000 | -9.3% | 1,943,054 | +19.6% | 6.30% | -16.3% |
| AUXL | New | AUXILIUM PHARMACEUTICALS INC | $44,583,000 | – | 1,493,560 | +100.0% | 6.12% | – |
| OFIX | Sell | ORTHOFIX INTL N V | $44,474,000 | -16.6% | 1,436,495 | -2.4% | 6.10% | -23.1% |
| INSYQ | Sell | INSYS THERAPEUTICS INC NEW | $43,430,000 | +17.0% | 1,119,917 | -5.8% | 5.96% | +8.0% |
| AKRXQ | Buy | AKORN INC | $42,562,000 | +150.0% | 1,173,485 | +129.2% | 5.84% | +130.6% |
| ABBV | Sell | ABBVIE INC | $33,449,000 | -3.1% | 579,100 | -5.3% | 4.59% | -10.6% |
| HPTX | Sell | HYPERION THERAPEUTICS INC | $31,854,000 | -4.6% | 1,263,034 | -1.3% | 4.37% | -12.0% |
| PTX | Buy | PERNIX THERAPEUTICS HLDGS IN | $26,443,000 | -2.7% | 3,443,137 | +13.8% | 3.63% | -10.2% |
| ANAC | Buy | ANACOR PHARMACEUTICALS INC | $25,413,000 | +61.4% | 1,038,553 | +16.9% | 3.49% | +48.9% |
| BIOS | Sell | BIOSCRIP INC | $21,794,000 | -33.9% | 3,153,952 | -20.2% | 2.99% | -39.0% |
| HMSY | Buy | HMS HLDGS CORP | $21,171,000 | -5.5% | 1,123,126 | +2.3% | 2.91% | -12.8% |
| OSIR | Sell | OSIRIS THERAPEUTICS INC NEW | $19,887,000 | -35.4% | 1,579,561 | -19.8% | 2.73% | -40.4% |
| ANIP | Buy | ANI PHARMACEUTICALS INC | $15,549,000 | +27.1% | 549,827 | +54.8% | 2.13% | +17.3% |
| RLYP | New | RELYPSA INC | $13,929,000 | – | 660,462 | +100.0% | 1.91% | – |
| RTRX | New | RETROPHIN INC | $13,886,000 | – | 1,539,459 | +100.0% | 1.91% | – |
| MACK | New | MERRIMACK PHARMACEUTICALS IN | $13,494,000 | – | 1,536,902 | +100.0% | 1.85% | – |
| DSCI | Buy | DERMA SCIENCES INC | $12,665,000 | -24.5% | 1,520,404 | +4.7% | 1.74% | -30.4% |
| PLX | New | PROTALIX BIOTHERAPEUTICS INC | $12,166,000 | – | 5,027,338 | +100.0% | 1.67% | – |
| HWAY | Sell | HEALTHWAYS INC | $11,185,000 | -25.0% | 698,190 | -17.9% | 1.54% | -30.8% |
| ADMA | Buy | ADMA BIOLOGICS INC | $8,002,000 | +23.0% | 776,863 | +16.5% | 1.10% | +13.4% |
| ASTM | New | AASTROM BIOSCIENCES INC | $6,706,000 | – | 2,352,940 | +100.0% | 0.92% | – |
| IG | New | IGI LABS INC | $6,704,000 | – | 719,278 | +100.0% | 0.92% | – |
| HSTM | New | HEALTHSTREAM INC | $4,174,000 | – | 173,833 | +100.0% | 0.57% | – |
| FURX | Exit | FURIEX PHARMACEUTICALS INC | $0 | – | -13,440 | -100.0% | -0.21% | – |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -630,178 | -100.0% | -1.41% | – |
| SUPN | Exit | SUPERNUS PHARMACEUTICALS INC | $0 | – | -1,440,008 | -100.0% | -2.35% | – |
| MYGN | Exit | MYRIAD GENETICS INC | $0 | – | -507,682 | -100.0% | -2.94% | – |
| IPCM | Exit | IPC THE HOSPITALIST CO INC | $0 | – | -573,209 | -100.0% | -3.77% | – |
| WX | Exit | WUXI PHARMATECH CAYMAN INC | $0 | – | -1,143,315 | -100.0% | -5.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.